In nonexperimental comparative effectiveness research using health care databases, outcome measurements must be validated to evaluate and potentially adjust for misclassification bias. We aimed to validate claims-based myocardial infarction (MI) algorithms in a Medicaid population using an HIV clinical cohort as the gold standard.
L arge health care databases are useful for conducting nonexperimental comparative effectiveness research. Although not perfect, the population is often closer to ideal than ad hoc studies because it is less selected, information on drug exposure in these sources is good for prescription drugs in the outpatient setting, the data are generally available, and their large sample size provides an opportunity to examine rare outcomes. 1 As these data are collected primarily for administrative purposes and not for research, however, outcome measurements should be validated to quantify or minimize bias due to misclassification.
Measures of accuracy, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) are used to quantify misclassification. Sensitivity and specificity generally assess outcome and exposure misclassification, whereas PPV and NPV are most often used for population selection. There is a tradeoff between maximizing sensitivity versus specificity in comparative effectiveness and safety studies and choice of measure should be based on the overarching study question. 2 In studies estimating relative effects, specificity is the most important outcome misclassification measure because a perfect specificity will lead to unbiased relative risk estimates even if sensitivity is low. 3 A high sensitivity allows for identification of most events and reduces bias of effect measures on the absolute scale [risk difference (RD) or number needed to treat]. 4 Many validation studies start with a large administrative health care database where algorithms to define events are validated against a gold standard (eg, medical records). These studies are only able to calculate PPVs and not sensitivity and specificity as they do not have access to the gold standard population without the event (true negatives).
Observational clinical cohort studies have contributed substantially to our understanding of the effectiveness of different antiretroviral treatments for HIV clinical management. [5] [6] [7] [8] [9] [10] Similarities and differences between clinical cohort studies and other more traditional observational studies (eg, interval cohorts) have been discussed elsewhere. 11 Briefly, participants in clinical cohort studies are enrolled as they seek or receive care and the medical record is the source for information collected on the participants. Despite their use to examine the effect of treatments in a real world setting, these studies may not reach adequate person-time of follow-up required to study rare events.
The accuracy of myocardial infarction (MI) ascertainment in administrative health care data has been assessed; however, most studies only present PPV due to the lack of true negatives needed to estimate sensitivity and specificity. [12] [13] [14] [15] [16] [17] Further, some validation studies used algorithms to identify MI events that may now be outdated due to changes in patient treatment and health care service and reimbursement. [15] [16] [17] For example, many current MI ascertainment algorithms contain a length of stay criteria Z3 days. Analyses of hospital discharge records from Minnesota and New England suggest that the median length of stay for patients hospitalized with MI is decreasing. 18, 19 These observations justify a periodic reassessment and validation of MI algorithms used for outcome ascertainment as changes occur in systems for diagnostic coding, health care practices, and reimbursement policies. 20, 21 By linking clinical cohort data to administrative health care data, it is possible to validate algorithms defining health outcomes of interest. In this study, we used the UNC HIV CFAR Clinical Cohort (UCHCC) study and the North Carolina (NC) Medicaid administrative data, to validate different claims-based definitions of MI within an HIV-infected population.
METHODS

Study Population
We used the UCHCC and NC Medicaid administrative data for this validation study. The UCHCC is a dynamic clinical cohort study initiated in 2000 and includes all HIVinfected patients that are Z18 years of age unless they are unable or unwilling to provide written informed consent in English or Spanish. The cohort includes data from different sources including existing hospital electronic databases, medical chart abstractions, in-person interviews, and data from federal agencies including mortality information. UCHCC participants are not seen at exact regular intervals, but rather as indicated by clinical care.
The Medicaid program is a joint state and federally funded program providing health care benefits to individuals of low income. Individuals qualify based on age, disability, income, and financial resources. 22 The Medicaid data contains health care service reimbursement information including doctor visits, hospital care, outpatient visits, treatments, emergency use, prescription medications, and diagnoses, procedures, and provider information. These data also include reimbursement information for Medicaid patients also enrolled in Medicare (dually eligible beneficiaries). We included all HIV-infected NC Medicaid beneficiaries and those dually eligible beneficiaries Z18 years of age with Medicaid enrollment between January 1, 2002 and December 31, 2008. HIV patients were identified in the Medicaid administrative data using the following definition: an ICD-9 code of 042 in any position or a prescription of any of the 27 FDA approved antiretrovirals between 2002 and 2008. Antiretrovirals were identified in the administrative data through National Drug Codes. Patients enrolled both in the UCHCC and Medicaid at any point between 2002 and 2008 formed the validation sample. For these patients we merged the UCHCC and the Medicaid administrative data based on social security number, first, and last name.
Validation Study Mechanics
We synchronized periods of continuous Medicaid eligibility with the UCHCC and included all patients in both Medicaid and UCHCC between 2002 and 2008 with at least 30 days of observation time in both data sources. Patients contributed observed time from the last of (i) January 1, 2002, (ii) entry into the UCHCC, or (iii) start of Medicaid enrollment. Patients' time was included until the first of (i) December 31, 2008, (ii) 12 months after the last documented CD4 count or HIV RNA measurement in the UCHCC, or (iii) >30 days without Medicaid enrollment. If a patient was lost to HIV care in the UCHCC (ie, >12 months without a documented CD4 count or HIV RNA measurement) or lost Medicaid coverage for >30 days but then reinitiated HIV care or Medicaid enrollment, this time at risk was not considered in these analyses. Among patients who died, observed time was stopped on the date of death.
Event Definitions
We included all patients that had either a definite or probable MI as defined in the UCHCC and Medicaid data sources during the study period. In an initial validation analysis, we included the first MI event documented in either the UCHCC or Medicaid occurring during the observed period and did not impose any restriction on dates of events when assessing validation parameters. In a secondary analysis, we accounted for multiple MI events per patient, timing of the event, and length of observed time in each source by creating standardized time increments (3, 6, 12, 24 mo) within the previously defined observed period. In order to maintain synchronicity between data sources and to account for differing lengths of follow-up time, if the observed period ended in the middle of the defined increment, that observation was not included in the analysis. Time increments were determined based on length of continuous follow-up often required for comparative effectiveness studies. Because of sample size constraints, we did not consider time increments >24 months.
MI Definition-UNC CFAR HIV Clinical Cohort (Gold Standard)
MI events were initially identified in the UCHCC through medical chart abstraction and adjudicated by health care personnel. The MI event definition expands upon the World Health Organization definition and includes serum markers, ECGs, and chest pain criteria. 23, 24 
MI Definition-Medicaid Administrative Claims
As we were interested in validation of incident MI events and most new MI events present to the hospital versus an outpatient setting, we used inpatient claims. The administrative data included claims for patients enrolled in Medicaid and those who were dually eligible for Medicaid and Medicare. Our initial MI event definition included a diagnosis code (ICD-9-CM) of 410.xx in the first or second position and a length of stay Z3 days as has been used in previous validation studies. [15] [16] [17] We then used varying algorithms to identify MI events to determine the algorithm that would best identify MI events in this population. The 12 algorithms considered included varying: (i) ICD-9 code 410.xx in first or second position, versus any position; (ii) length of stay as any number of day, Z1 day, and Z3 days; and (iii) inclusion of diagnosis-related group codes 121, 122, and 123.
Statistical Analysis
We examined basic baseline demographic and clinical characteristics of the NC Medicaid population, the UCHCC and the validation sample for the enrollees identified with an MI in the gold standard. We then cross-tabulated MI events identified in both cohorts based on the definitions outlined above to estimate sensitivity (proportion of true MI events identified in Medicaid among all gold standard defined MI events), specificity (proportion of true nonevents identified in Medicaid among all gold standard defined nonevents), PPV (proportion of true MI events identified in Medicaid among all MI events identified in Medicaid), and NPV (proportion of true nonevents identified in Medicaid among all nonevents identified in Medicaid). Exact binomial 95% confidence intervals (CI) quantified the precision around each validation measure. 25 For our secondary analysis, intercept only generalized estimating equation models with a binomial distribution, independent correlation structure, and logit link estimated sensitivity and specificity. These characteristics were calculated for the 3-, 6-, 12-, and 24-month time increments.
Finally, we explored the impact of outcome misclassification on relative risk and absolute risk estimates in a hypothetical population of 1100 individuals, a baseline probability of exposure of 0.09, and a risk of MI of 0.1 in the exposed and 0.08 in the unexposed to a hypothetical risk factor [true risk ratio (RR), 1.25; true RD, 0.02]. We used sensitivities and specificities estimated from our validation study to calculate the expected percent bias in the estimated RR and RD under different definitions of MI assuming no misclassification of exposure and nondifferential outcome misclassification. We used the following equations to calculate the observed RR and RD: where a = SensitivityÂ proportion exposedÂ risk in exposed+ (1À specificity)Â proportion exposedÂ (1À risk in exposed); b = (1À sensitivity)Â proportion exposedÂ risk in exposed +specificityÂ proportion exposedÂ (1À risk in exposed); c = SensitivityÂ (1À proportion exposed)Â incidence in the unexposed+(1À specificity)Â (1À proportion exposed)Â (1À risk in unexposed); d = (1À sensitivity)Â (1À proportion exposed)Â incidence in the unexposed+specificityÂ (1À proportion exposed)Â (1À risk in unexposed).
We quantified the percent bias for both RR and RD using the following equation:
100 RD true ÀRD observed / RD true ð Þ :
All analyses were conducted using SAS version 9.2 or Intercooled Stata11. The study was approved by the University of North Carolina Committees on the protection of the Rights of Human Subjects.
RESULTS
Between 2002 and 2008 there were 1,134,986 NC Medicaid beneficiaries Z18 years of age of whom 13,006 patients were HIV infected based on an ICD-9 or antiretroviral use criteria. Of 2340 HIV-infected patients in the UCHCC who received care between 2002 and 2008, 1204 patients were also Medicaid beneficiaries. There were 141 UCHCC and Medicaid beneficiaries that were not included as they either did not have sufficient follow-up time in either data source or the period of Medicaid eligibility did not overlap with follow-up time in the UCHCC, leaving 1063 patients included in the validation sample (Fig. 1 ). The median length of observed time for the validation population was 2.5 years (interquartile range: 0.9, 4.7; full range: 0.2, 7.0). The distribution of most demographic and clinical characteristics of the overall Medicaid population, UCHCC, and validation sample were similar ( Table 1 ). The overall Medicaid population and validation sample had a greater proportion of black, women, and younger patients when compared with the UCHCC, whereas the validation sample had a larger proportion of intravenous drug users. Clinically, patients included in the validation sample had similar log HIV RNA and CD4 cell counts at entry into care at UNC. In the validation sample, 17 patients had an MI event that occurred during their observation period and there were 19 total MI events.
The validation test characteristics comparing MI events in the UCHCC with those identified in the Medicaid data using varying algorithms are displayed in Table 2 . The current most frequent algorithm used to identify MI events in administrative data, ICD-9 410.xx code in the first or second position and a length of stay Z3 days, resulted in a calculated sensitivity of 0.588 (95% CI, 0.329-0.816) and a specificity of 0.994 (95% CI, 0.988-0.998). Removing the length of stay criteria increased sensitivity to 0.647 (95% CI, 0.383-0.857) and decreased specificity to 0.988 (95% CI, 0.980-0.994). The position of the diagnosis code also influenced validation parameters. Allowing the ICD 9-code 410.xx to be present in any of the 9 ICD-9 code positions, whereas keeping the Z3 day length of stay requirement increased the sensitivity of MI identification to 0.765 (95% CI, 0.501-0.932). Removing the position and length of stay requirement resulted in the highest sensitivity and lowest specificity of event ascertainment (sensitivity = 0.823; 95% CI, 0.566-0.962; specificity = 0.982; 95% CI, 0.972-0.999). Overall PPVs were low for all of the algorithms explored (range, 0.438-0.625), whereas NPVs remained consistently high (range, 0.993-0.997). The addition of diagnosis-related group codes 121, 122, 123 did not appreciably change validation parameters (data not shown).
We also examined the effect of length of observation, timing of events, and multiple MI events per patient. For this analysis we used the most commonly used MI ascertainment criteria in the literature (ICD-9 code 410.xx in first or second position and a length of stay Z3 d). As we required the entire length of time for each time increment, the number of unique patients included decreased as increments increased from 3 to 24 months (1007 to 598 patients, respectively). When allowing for a 24-month increment of observed time, sensitivity and specificity measurements were similar to those in the first validation analysis (sensitivity = 0.538, 95% CI, 0.268-0.788; specificity = 0.998, 95% CI, 0.993-0.999). Sensitivity was lowest when allowing for only a 3-month period of eligibility for the event to occur in both data sources (0.444; 95% CI, 0.250-0.658), and increased for the 6-and 12-month incremental periods (0.516, 95% CI, 0.314-0.713 and 0.600, 95% CI, 0.338-0.815, respectively; Fig. 2) . A similar relationship between length of observed time and sensitivity and specificity was observed for the other MI algorithms. For all algorithms, the maximum sensitivity was observed when the standardized 12-month time increment was used (data not shown). Table 3 displays the effect of outcome misclassification in a hypothetical population using sensitivity and specificity measures from the following algorithms: (1) ICD-9 code 410.xx in the first or second position and length of stay Z3 days; (2) ICD-9 code 410.xx in first or second position and a length of stay Z1 day; and (3) ICD-9 code 410.xx in any position and any length of stay. Given a population of 1100 individuals, a baseline probability of exposure to a hypothetical risk factor of 0.09 and a risk of MI of 0.1 in the exposed and 0.08 in the unexposed (true RR, 1.25; true RD: 0.02); a sensitivity of 0.588 and a specificity of 0.994 will result in an observed RR of 1.21 and an observed RD of 0.015. A sensitivity of 0.824 and a specificity of 0.982 would result in a RR of 1.10 and a RD of 0.009. An assessment of bias reveals that the percent bias is highest for both relative and absolute measures when specificity is the lowest.
DISCUSSION
We examined sensitivity, specificity, PPV, and NPV of various algorithms to identify MI events among HIV-infected individuals enrolled in the NC Medicaid program relying on events adjudicated in the UCHCC as the gold standard. We found that using our best algorithm for relative effect measures, we achieved a specificity of 0.994 translating to a bias of around 11% based on plausible parameter values for a study of antiretrovirals on risk of MI using administrative health care data. In general specificity measures using all ascertainment algorithms were high (0.982-0.994); Compared with other studies, the sensitivity of a commonly used algorithm to identify MIs (ICD-9 code 410.xx in the first or second position and length of stay Z3 days), was low in our study (0.59). Other studies reported sensitivities ranging from 0.65 to 0.83. 13, 26 The observed sensitivities may be explained by our study population and ICD-9 code position. HIV patients are often admitted to the hospital for HIV-related and general medical comorbidities and an MI event occurring during a hospital stay may not get coded in the first or second ICD-9 code position. Therefore, an expansion of the criteria to include all ICD-9 code positions would increase the sensitivity of the ascertainment criteria as we observed. Rosamond 26 noted that sensitivities of ICD-9 code 410.xx also have declined over time; in part due to changes in diagnostic practices and the use of differing algorithms for defining MI in the gold standard.
We investigated other diagnoses in the Medicaid data or the UCHCC for patients that remained misclassified FIGURE 2. Sensitivity and false-positive rate for claims-based identification of myocardial infarctions allowing for varying periods of continuous eligibility (3, 6, 12, 24 mo) . Myocardial infarction events were identified by ICD-9 code 410.xx in the first or second position and a length of stay Z3 days. *In this hypothetical population of 1100 patients, the true risk of a hypothetical adverse event in patients exposed to a hypothetical medication is 0.1, the true risk of the same hypothetical adverse event unexposed to the medication in this population is 0.08. The probability of medication exposure in the population is 0.09. despite the use of the most sensitive or most specific algorithms (3 false negatives and 6 false positives, respectively). Using the most sensitive algorithm, 3 patients had an MI in the gold standard. Two of these patients had ICD-9 codes for non-MI, cardiovascular-related conditions, on or around the diagnosis date identified by the gold standard (unspecified chest pain and precordial pain; coronary atherosclerosis of native coronary artery). The third patient did not have any ICD-9 codes related to cardiovascular disease conditions coded on or around the date of diagnosis in the UCHCC. Using the most specific algorithm, there were 6 patients with a claim for an MI in the administrative data that did not have an MI in the UCHCC. Five out of 6 of these patients did have other, non-MI, cardiovascular-related conditions in the UCHCC. The sixth patient did not have any cardiovascular conditions noted but did have a history of drug abuse.
We also addressed the impact of varying lengths of observed time, timing of events, and multiple MI events on ascertainment criteria performance. Sensitivity was lowest for the shortest time increment indicating that dates recorded for events in the Medicaid data were not the same as dates recorded in the UCHCC. Sensitivities for the 6-and 12month intervals were similar to those calculated in the first validation study. The decrease in sensitivity for the 24-month time frame was likely due to the reduction in number of patients with at least 24 months of observed time for analysis. These results suggest that a requirement for a full 12 months of eligibility in Medicaid may maximize the sensitivity of claims-based MI identification algorithm.
PPVs calculated using the differing MI ascertainment algorithms in our study were substantially lower than the values obtained from previous studies (0.93-0.97). 12, [15] [16] [17] These results are likely due to the low prevalence of MI in this population. However, while PPV is an important measure for some research questions, this measure has less importance in the context of comparative effectiveness research. Nevertheless, the low PPVs suggest that the administrative health care data used here may not be ideal for the selection of a study cohort.
Chubak et al 27 and Setoguchi et al 28 explored bias related to outcome misclassification in a hypothetical population (Chubak) and a Medicare population (Setoguchi) . Their results quantified outcome misclassification bias on a relative scale, but did not address misclassification bias on an absolute scale. Often absolute measures, like the RD, are used in comparative safety and effectiveness studies; therefore addressing the impact of less than perfect specificity and sensitivity on both types of effect measures is warranted. In our hypothetical example, as expected, deviations from perfect specificity led to biased results on the relative scale, whereas increases in sensitivity decreased bias on the absolute scale. However, both sensitivity and specificity influenced absolute measures. Although a perfect specificity decreases the bias of relative effect measures, the reduction of the number of cases identified may decrease precision around estimates substantially. Therefore, the choice of ascertainment algorithm used should be prioritized based on the study question, using the specific validation parameter that will minimize bias while maximizing precision. For this HIV Medicaid population, it may be important to use an algorithm that expands the ICD-9 code position requirement to maximize sensitivity with minimal decreases in specificity.
Our study has limitations. The number of events obtained for validation was low that influenced the precision around our measurements. Further, we intentionally conducted this study in a Medicaid HIV population limiting the generalizability of these algorithms to other populations or data sources. Despite these limitations, our study has important implications. As this population includes patients seeking care throughout the state of NC, we will be able to examine the effects of antiretrovirals on MI in a more generalized population. Each ascertainment algorithm had relatively high specificity and can be used to conduct comparative effectiveness studies examining the relationship between antiretroviral use and MI outcomes in the NC Medicaid population. Finally, the measures of validity reported here may be used by other researchers to assess the role of outcome misclassification in studies using administrative health care databases.
